Let's look at the charts and indicators to round out the picture.
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
How do the charts and indicators look ahead of their quarterly release?
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
ABT is pointed up after trading in a choppy range since October.
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Experienced traders could approach the long side carefully.
The charts indicate that buyers of Aurinia have been more aggressive in recent weeks after a period of consolidation.
One of pharma's biggest CEO's talks M&A action on the exchange.